CCR-3 receptor antagonists (I)
    2.
    发明授权
    CCR-3 receptor antagonists (I) 失效
    CCR-3受体拮抗剂(I)

    公开(公告)号:US07019007B2

    公开(公告)日:2006-03-28

    申请号:US10306820

    申请日:2002-11-27

    CPC分类号: C07D211/18

    摘要: The invention provides compounds of Formula (I): wherein: R1–R4, A, D, and L have any of the values defined in the specification that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use, and methods and intermediates useful for preparing them.

    摘要翻译: 本发明提供式(I)的化合物:其中:R 1 -R 4,A,D和L具有说明书中定义的任何值为CCR -3受体拮抗剂,含有它们的药物组合物,其使用方法,以及可用于制备它们的方法和中间体。

    Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

    公开(公告)号:US06576653B2

    公开(公告)日:2003-06-10

    申请号:US10117370

    申请日:2002-04-05

    申请人: Daisy Joe Du Bois

    发明人: Daisy Joe Du Bois

    IPC分类号: A61K31407

    摘要: This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

    Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
    6.
    发明授权
    Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors 失效
    双环吡咯酰胺作为糖原磷酸化酶抑制剂

    公开(公告)号:US06399601B1

    公开(公告)日:2002-06-04

    申请号:US09670759

    申请日:2000-09-27

    申请人: Daisy Joe Du Bois

    发明人: Daisy Joe Du Bois

    IPC分类号: A61K315355

    摘要: This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compound of Formula I, and to methods of treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, or tissue ischemia.

    摘要翻译: 本发明涉及式I或其立体异构体的化合物,其药学上可接受的盐或前药或其药学上可接受的盐。 本发明还涉及包含式I化合物的药物组合物和治疗糖尿病,胰岛素抵抗,糖尿病性神经病,糖尿病性肾病,糖尿病性视网膜病,白内障,高血糖症,高胆固醇血症,高血压,高胰岛素血症,高脂血症,动脉粥样硬化或组织的方法 缺血。